Differences in hemoglobin levels and mean weekly erythropoietin stimulating agent (ESA) doses before and after the exposure period. The figure represents the difference in means of hemoglobin levels and mean weekly doses corrected for body weight (units/kg).
Odds ratios for IV iron administration strategy with achievement of anemia management goals
| Anemia management goals | Maintenance (n = 4511) | Non-maintenance (n = 8458) | P-value |
|---|---|---|---|
| Achievement of hemoglobin 10–12 g/dL | |||
| Crude | 0.95 (0.88–1.03) | Reference | 0.19 |
| Adjusted | 1.01 (0.93–1.09) | Reference | 0.86 |
| Reduction in mean weekly ESA dose of 25% or more | |||
| Crude | 1.33 (1.18–1.49) | Reference | < 0.01 |
| Adjusted | 1.15 (1.02–1.30) | Reference | 0.02 |
| Mortality | Maintenance n = 4708 | Non-maintenance n = 9145 | |
| Crude | 0.52 (0.44–0.62) | Reference | < 0.01 |
| Adjusted | 0.73 (0.62–0.86) | Reference | < 0.01 |
| Anemia management goals | Maintenance (n = 4511) | Non-maintenance (n = 8458) | P-value |
|---|---|---|---|
| Achievement of hemoglobin 10–12 g/dL | |||
| Crude | 0.95 (0.88–1.03) | Reference | 0.19 |
| Adjusted | 1.01 (0.93–1.09) | Reference | 0.86 |
| Reduction in mean weekly ESA dose of 25% or more | |||
| Crude | 1.33 (1.18–1.49) | Reference | < 0.01 |
| Adjusted | 1.15 (1.02–1.30) | Reference | 0.02 |
| Mortality | Maintenance n = 4708 | Non-maintenance n = 9145 | |
| Crude | 0.52 (0.44–0.62) | Reference | < 0.01 |
| Adjusted | 0.73 (0.62–0.86) | Reference | < 0.01 |
ESA is erythropoietin stimulating agent. Adjusted analyses include demographic, clinical and treatment parameters (age, sex, race, ethnicity, cause of end-stage renal disease, comorbidity and year of dialysis initiation), total iron dose during the exposure period, measures of iron stores (transferrin saturation and ferritin) and hemoglobin at the start of the exposure period, mean weekly erythropoietin stimulating agent dose in units/kg during the exposure period and pro-infectious and pro-inflammatory parameters (vascular access, serum albumin, serum creatinine and recent infection).
Odds ratios for IV iron administration strategy with achievement of anemia management goals
| Anemia management goals | Maintenance (n = 4511) | Non-maintenance (n = 8458) | P-value |
|---|---|---|---|
| Achievement of hemoglobin 10–12 g/dL | |||
| Crude | 0.95 (0.88–1.03) | Reference | 0.19 |
| Adjusted | 1.01 (0.93–1.09) | Reference | 0.86 |
| Reduction in mean weekly ESA dose of 25% or more | |||
| Crude | 1.33 (1.18–1.49) | Reference | < 0.01 |
| Adjusted | 1.15 (1.02–1.30) | Reference | 0.02 |
| Mortality | Maintenance n = 4708 | Non-maintenance n = 9145 | |
| Crude | 0.52 (0.44–0.62) | Reference | < 0.01 |
| Adjusted | 0.73 (0.62–0.86) | Reference | < 0.01 |
| Anemia management goals | Maintenance (n = 4511) | Non-maintenance (n = 8458) | P-value |
|---|---|---|---|
| Achievement of hemoglobin 10–12 g/dL | |||
| Crude | 0.95 (0.88–1.03) | Reference | 0.19 |
| Adjusted | 1.01 (0.93–1.09) | Reference | 0.86 |
| Reduction in mean weekly ESA dose of 25% or more | |||
| Crude | 1.33 (1.18–1.49) | Reference | < 0.01 |
| Adjusted | 1.15 (1.02–1.30) | Reference | 0.02 |
| Mortality | Maintenance n = 4708 | Non-maintenance n = 9145 | |
| Crude | 0.52 (0.44–0.62) | Reference | < 0.01 |
| Adjusted | 0.73 (0.62–0.86) | Reference | < 0.01 |
ESA is erythropoietin stimulating agent. Adjusted analyses include demographic, clinical and treatment parameters (age, sex, race, ethnicity, cause of end-stage renal disease, comorbidity and year of dialysis initiation), total iron dose during the exposure period, measures of iron stores (transferrin saturation and ferritin) and hemoglobin at the start of the exposure period, mean weekly erythropoietin stimulating agent dose in units/kg during the exposure period and pro-infectious and pro-inflammatory parameters (vascular access, serum albumin, serum creatinine and recent infection).
